US vaccine maker Novavax said on Monday that its vaccine is highly effective against Covid-19 and provides protection against all forms of the coronavirus. This has come to the fore in a large and final phase study conducted in the US and Mexico. The company said that the vaccine is 90 percent effective overall.
Novavax vaccine can be stored at standard refrigerator temperature and is easy to dispense. The Novavax vaccine is easy to store and transport and is expected to play a key role in expanding the supply of the vaccine to developing countries.
The company said it plans to seek approval for the vaccine for use in the US, Europe and elsewhere by the end of September, and by then it will be able to produce 100 million doses a month. “Many of our initial doses will go to low- and middle-income countries,” said Stanley Erk, chief executive of Novavax.
Novavax’s study involved nearly 30,000 people aged 18 and older in the US and Mexico. Two thirds of them were given two doses of vaccine spaced three weeks apart while the rest were given ineffective (dummy) vaccine. There were 77 cases of Covid-19, of which 14 were from the group that was given the vaccine while the remaining cases were in those who were given the ineffective (dummy) vaccine. None of the vaccinated groups had a moderate or severe disease.
The vaccine was effective on many forms of the virus, including the one that appeared in Britain, which has spread widely in the US. In addition, the vaccine was effective on high-risk groups, including the elderly and those with health problems. Erk said the side effects were mostly minor and there was pain at the injection site. No blood clots or heart problems were detected.